On July 17, ImmunityBio fell 5.11% in regular trading, trading at $7.345/share, with turnover of $32.31 million. The decline extends a multi-session pullback driven by sector-wide profit-taking in U.S. biotech stocks.

The U.S. biotech sector has come under sustained selling pressure after accumulating approximately 25% gains over the prior month. Funds have been rotating structurally from high-beta small-cap biotech names toward large-cap defensive pharmaceutical stocks. ImmunityBio, as one of the stronger-performing small-cap biotech names year-to-date, has experienced continued retracement absent any company-specific fundamental negatives, reflecting the broader sector de-risking trend.

Within the Biotechnology sector, the rotation pattern is evident: large-cap names AbbVie up 3.37%, Amgen up 3.13%, Gilead Sciences up 2.73%, and Vertex Pharmaceuticals up 1.83%, while high-beta peer Moderna fell 5.95%.

ImmunityBio is a clinical-stage immunotherapy company whose core product Anktiva is approved in 33 countries for bladder cancer and lung cancer treatment. The company reported Q1 product revenue of $44.2 million, up 168% year-over-year, and holds $381 million in cash and marketable securities.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)